Detail akcie Lexicon Pharma online

Business Summary: Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focusing on the research and development of pilavapadin, LX9851 and sotagliflozin and the commercialization of INPEFA. It is developing pilavapadin (LX9211), an orally delivered small molecule drug candidate, as a treatment for neuropathic pain. It has completed three Phase II clinical trials evaluating the safety and tolerability of pilavapadin and its effects on diabetic peripheral neuropathic pain (DPNP) and neuropathic pain. It is developing LX9851, an orally delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic disorders and is conducting preclinical development of LX9851 in preparation for filing an investigational new drug application. It is commercializing INPEFA (sotagliflozin), an orally delivered small molecule drug, in the United States to reduce the risk of cardiovascular death, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Lexicon Pharmaceuticals Inc revenues increased from $2.8M to $30.1M. Net loss decreased 78% to $22M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Personnel expenses decrease of 74% to $8.6M (expense), General and administrative - other decrease of 71% to $9.3M (expense).